European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - tiotropium bromide monohydrate 3.125ug equivalent to tiotropium 2.5 µg/dose - solution for inhalation - 2.5 mcg/dose - active: tiotropium bromide monohydrate 3.125ug equivalent to tiotropium 2.5 µg/dose excipient: benzalkonium chloride disodium edetate hydrochloric acid purified water - spiriva respimat is indicated for the long term once daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva reduces the frequency of exacerbations and improves exercise tolerance and health-related quality of life.

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - olodaterol hydrochloride 0.0248%{relative} equivalent to to olodaterol 2.5mcg per actuation; tiotropium bromide monohydrate 0.0283%{relative} equivalent to to tiotropium 2.5mcg per actuation - solution for inhalation - 2.5mcg/2.5mcg - active: olodaterol hydrochloride 0.0248%{relative} equivalent to to olodaterol 2.5mcg per actuation tiotropium bromide monohydrate 0.0283%{relative} equivalent to to tiotropium 2.5mcg per actuation excipient: benzalkonium chloride disodium edetate hydrochloric acid purified water - spiolto respimat is indicated for the long term, once daily maintenance treatment in patients with copd (including chronic bronchitis and emphysema), to reduce airflow obstruction, to improve quality of life, and to reduce associated dyspnoea.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - tiotropium bromide - inhalation powder hard capsules - tiotropium bromide 18 mcg - tiotropium bromide - tiotropium bromide - tiotropium is a bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 180.6 mg (equivalent: nintedanib, qty 150 mg) - capsule, soft - excipient ingredients: iron oxide red; titanium dioxide; hard fat; lecithin; gelatin; glycerol; iron oxide yellow; medium chain triglycerides; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 120.4 mg (equivalent: nintedanib, qty 100 mg) - capsule, soft - excipient ingredients: hard fat; lecithin; glycerol; iron oxide red; gelatin; medium chain triglycerides; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 25 mg - tablet, multilayer - excipient ingredients: maize starch; sorbitol; sodium hydroxide; iron oxide yellow; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; sodium starch glycollate type a; meglumine - micardis plus is indicated for the treatment of hypertension. treatment should not be intitiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sodium hydroxide; sorbitol; microcrystalline cellulose; iron oxide red; maize starch; lactose monohydrate; povidone; sodium starch glycollate - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: povidone; sodium hydroxide; microcrystalline cellulose; lactose monohydrate; sorbitol; sodium starch glycollate; maize starch; meglumine; magnesium stearate; iron oxide red - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sodium hydroxide; sorbitol; meglumine - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)